

Subject: Re: ISMRM 2024 Annual Meeting Notification for Abstract Tracking Number 8406

From: Jia Guo <jg3400@columbia.edu>

Date: 1/25/2024, 13:23

To: "Mela, Angeliki" <am2904@cumc.columbia.edu>, Zhonghui Qie <zq2213@columbia.edu>, Yanting Yang <yy3189@columbia.edu>, "Canoll, Peter D." <pc561@cumc.columbia.edu>

CC: ismrm2024@mirasmart.com

Dear all,

I am thrilled to share some fantastic news with all of you! See below.

Our collective efforts and dedication have truly paid off, as our work has been chosen for an in-person Oral Scientific Session at the prestigious 2024 ISMRM & ISMRT Annual Meeting. This achievement is particularly notable given the highly competitive nature of the selection process for oral presentations.

I want to extend my heartfelt congratulations to each one of you for your invaluable contributions and relentless commitment to our project. It's a testament to our team's expertise, collaboration, and hard work.

Best regards,
Jia

On Thu, Jan 25, 2024 at 4:16 PM <ISM2024@mirasmart.com> wrote:

Re: "Detecting IDH1 Mutations in Gliomas: Insights from J-Difference Editing MEGA-PRESS 1H-MRS"

Dear Colleague:

Thank you for submitting an abstract to be considered for presentation at the scientific sessions of the 2024 ISMRM & ISMRT Annual Meeting & Exhibition in Singapore on 04 - 09 May 2024.

I am pleased to inform you that your abstract (title above) has been selected for presentation in an in-person Oral Scientific session. Additional session guidelines and detailed presentation instructions will be sent soon.

Your presentation is tentatively scheduled during the following oral scientific session:

Session: Cancer Biomarkers: Bench to Bedside

Day/Date: Tuesday, 07 May 2024

Session Time: 13:30

We are asking ALL presenters in Oral Scientific sessions to please confirm their intent to present in person using this link. Note that even if you cannot present in person, you will have an option for your abstract to remain in the Proceedings.

Please click this link:

<http://submissions.mirasmart.com/ISMRM2024/SubmissionInvitation.aspx?sid=AliwHhSlb>

The tentative schedule will be posted on the ISMRM website at www.ismrm.org/24m/. Program numbers will be assigned in March. Please note that the precise date and time of your presentation may still change, though we will make every effort to avoid a major reallocation. Please check the program closer to the meeting date in order to see the definitive day and time.

The oral presentation will consist of a 9-minute talk followed by maximum 3 minutes of questions by the audience. Some oral sessions will include a 12-minute introduction and/or guided discussion, and if this applies to your session, the moderators will contact you with more details.

Authors who submitted more than one abstract will receive a separate letter indicating the outcome for each submission.

Stipend Notifications

Educational, Clinical, New Entrant, and E. K. Zavoisky Stipend applicants should NOT register for the meeting until they have been notified of the status of their stipend application. Notifications of stipend awards will be sent out within the next few weeks.

Identifying Products and Discussing Unlabeled Uses of Products

As these sessions will offer Continuing Medical Education (CME) credits, presenters are required to observe the following ISMRM policies regarding the content of CME presentations:

1. The content of CME activities does not promote the proprietary interests of any commercial entities.
2. Content must be restricted to pure science, industry issues, and operation of devices, and should not include any advertising, corporate logos, trade names or a product group message of an ACCME Ineligible Company. Link to ACCME-defined ineligible company: <https://www.accme.org/accreditation-rules/standards-for-integrity-independence-accredited-ce/eligibility>
3. All recommendations involving clinical medicine must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients.
4. All scientific research referred to, reported or used in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.
5. Generic and Trade Names: Presentations must give a balanced view of therapeutic options. Speaker use of generic names will contribute to this impartiality. If trade names are used, those of several companies must be used rather than only that of a single manufacturer.
6. Unlabeled Uses of Products: When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during a presentation, the speaker is required to disclose that the product is not labeled for the use under discussion or that the product is still investigational. When you submitted your abstract, you agreed to abide by all these policies. Please be certain to comply with them during your presentation.

The meeting Proceedings will be published online only, with the full text of all accepted abstracts

available to advance registrants on 19 April 2024. Submission of your work constituted a commitment by the author(s) to present. Unexcused failure to present will jeopardize participation in future ISMRM programs.

For a list of all abstracts accepted for presentation at the Annual Meeting, please go to https://www.ismrm.org/24/accepted_abstracts.pdf.

The deadline for early registration is 04 April 2024. Please visit <https://www.ismrm.org/24m/> for more information.

On behalf of the Annual Meeting Program Committee, I thank you in advance for your participation in this year's meeting. Our members and attendees look forward to learning more about your work.

Best regards,

Brian Hargreaves, Ph.D.

2024 ISMRM Program Chair